08.18.26 -- Building Platform Strategies Instead Of One Off Vector Solutions

Discover methods to maintain high cell viability during scale-up while efficiently engineering difficult-to-transfect targets like primary and stem cells in advanced therapy development.

Watch experts detail single-use bioreactor mechanics, mixing capabilities, sparge technologies, and reliable scale-up strategies from early bench research to full production.

Industry leaders share risk-based strategies for identifying and measuring residual cryoprotectants and excipients in stem cell therapies to help ensure patient safety standards.

Review the demands for AAV manufacturing using a suspension process and the DOE-based strategy used to achieve a scalable process both in terms production and quality of AAV purified.

Explore proven strategies to maximize cell bank performance, implement closed processing controls, and adapt your manufacturing workflows to meet evolving Annex 1 guidelines.

Uncover operational principles and quality standards that drive successful commercial scale-up, helping developers navigate complex cGMP cell and gene therapy manufacturing.

In this segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, share lessons from their own organizations on balancing innovation with practical development.